Human lung microvascular endothelial cells as potential alternatives to human umbilical vein endothelial cells in bio-3D-printed trachea-like structures.
Cell Differentiation
/ genetics
Cell Proliferation
/ genetics
Chondrocytes
/ cytology
Endothelial Cells
/ ultrastructure
Human Umbilical Vein Endothelial Cells
/ ultrastructure
Humans
Lung
/ growth & development
Mesenchymal Stem Cells
/ cytology
Neovascularization, Physiologic
/ genetics
Printing, Three-Dimensional
Tissue Scaffolds
Trachea
/ growth & development
Bio-3D printer
Endothelial cell
Tracheal tissue-engineering
iPSC (induced pluripotent stem cell)
Journal
Tissue & cell
ISSN: 1532-3072
Titre abrégé: Tissue Cell
Pays: Scotland
ID NLM: 0214745
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
27
08
2019
revised:
29
11
2019
accepted:
02
12
2019
entrez:
1
4
2020
pubmed:
1
4
2020
medline:
18
11
2020
Statut:
ppublish
Résumé
We have been trying to produce scaffold-free structures for airway regeneration using a bio-3D-printer with spheroids, to avoid scaffold-associated risks such as infection. Previous studies have shown that human umbilical vein endothelial cells (HUVECs) play an important role in such structures, but HUVECs cannot be isolated from adult humans. The aim of this study was to identify alternatives to HUVECs for use in scaffold-free structures. Three types of structure were compared, made of chondrocytes and mesenchymal stem cells with HUVECs, human lung microvascular endothelial cells (HMVEC-Ls), and induced pluripotent stem cell (iPSC)-derived endothelial cells. No significant difference in tensile strength was observed between the three groups. Histologically, some small capillary-like tube formations comprising CD31-positive cells were observed in all groups. The number and diameters of such formations were significantly lower in the iPSC-derived endothelial cell group than in other groups. Glycosaminoglycan content was significantly lower in the iPSC-derived endothelial cell group than in the HUVEC group, while no significant difference was observed between the HUVEC and HMVEC-L groups. HMVEC-Ls can replace HUVECs as a cell source for scaffold-free trachea-like structures. However, some limitations were associated with iPSC-derived endothelial cells.
Sections du résumé
BACKGROUND
BACKGROUND
We have been trying to produce scaffold-free structures for airway regeneration using a bio-3D-printer with spheroids, to avoid scaffold-associated risks such as infection. Previous studies have shown that human umbilical vein endothelial cells (HUVECs) play an important role in such structures, but HUVECs cannot be isolated from adult humans. The aim of this study was to identify alternatives to HUVECs for use in scaffold-free structures.
METHODS
METHODS
Three types of structure were compared, made of chondrocytes and mesenchymal stem cells with HUVECs, human lung microvascular endothelial cells (HMVEC-Ls), and induced pluripotent stem cell (iPSC)-derived endothelial cells.
RESULTS
RESULTS
No significant difference in tensile strength was observed between the three groups. Histologically, some small capillary-like tube formations comprising CD31-positive cells were observed in all groups. The number and diameters of such formations were significantly lower in the iPSC-derived endothelial cell group than in other groups. Glycosaminoglycan content was significantly lower in the iPSC-derived endothelial cell group than in the HUVEC group, while no significant difference was observed between the HUVEC and HMVEC-L groups.
CONCLUSIONS
CONCLUSIONS
HMVEC-Ls can replace HUVECs as a cell source for scaffold-free trachea-like structures. However, some limitations were associated with iPSC-derived endothelial cells.
Identifiants
pubmed: 32223949
pii: S0040-8166(19)30366-0
doi: 10.1016/j.tice.2019.101321
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101321Informations de copyright
Copyright © 2019. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declarations of Competing Interest KN is a co-founder and shareholder of Cyfuse Biomedical K.K., Tokyo, Japan (Cyfuse). Declarations of interest for the remaining authors [DT, KM, RM, YT, AE, YT, SO, TT, MM, KT, MK, TT, TM, GH, NM, TN]: none.